SciBase Holding (STO:SCIB) Third Quarter 2024 Results
Key Financial Results
- Revenue: kr8.41m (up 16% from 3Q 2023).
- Net loss: kr17.8m (loss widened by 39% from 3Q 2023).
- kr0.081 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
SciBase Holding Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 5.8%. Earnings per share (EPS) also surpassed analyst estimates by 5.9%.
Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Sweden.
Performance of the Swedish Medical Equipment industry.
The company's shares are down 11% from a week ago.
Risk Analysis
Be aware that SciBase Holding is showing 6 warning signs in our investment analysis and 5 of those make us uncomfortable...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:SCIB
SciBase Holding
A medical technology company, develops and sells point-of-care platforms that utilizes electrical impedance spectroscopy for the evaluation of skin disorders in Europe, the United States, North America, Asia, Oceania, and internationally.
Medium-low with adequate balance sheet.
